|
1
|
Kyle RA and Rajkumar SV: Multiple myeloma.
N Engl J Med. 351:1860–1873. 2004. View Article : Google Scholar
|
|
2
|
Richardson PG, Mitsiades CS, Hideshima T
and Anderson KC: Novel biological therapies for the treatment of
multiple myeloma. Best Pract Res Clin Haematol. 18:619–634. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dimopoulos MA, San-Miguel JF and Anderson
KC: Emerging therapies for the treatment of relapsed or refractory
multiple myeloma. Eur J Haematol. 86:1–15. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Duan S, Skaar JR, Kuchay S, et al: mTOR
generates an auto-amplification loop by triggering the βTrCP- and
CK1α-dependent degradation of DEPTOR. Mol Cell. 44:317–324.
2011.PubMed/NCBI
|
|
5
|
Peterson TR, Laplante M, Thoreen CC, et
al: DEPTOR is an mTOR inhibitor frequently overexpressed in
multiple myeloma cells and required for their survival. Cell.
137:873–886. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhao Y, Xiong X and Sun Y: DEPTOR, an mTOR
inhibitor, is a physiological substrate of SCF(βTrCP) E3 ubiquitin
ligase and regulates survival and autophagy. Mol Cell. 44:304–316.
2011.PubMed/NCBI
|
|
7
|
Morgensztern D and McLeod HL:
PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer
Drugs. 16:797–803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hennessy BT, Smith DL, Ram PT, Lu Y and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wullschleger S, Loewith R and Hall MN: TOR
signaling in growth and metabolism. Cell. 124:471–484. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Edinger AL and Thompson CB: Defective
autophagy leads to cancer. Cancer Cell. 4:422–424. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gozuacik D and Kimchi A: Autophagy as a
cell death and tumor suppressor mechanism. Oncogene. 23:2891–2906.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Maiuri MC, Zalckvar E, Kimchi A and
Kroemer G: Self-eating and selfkilling: crosstalk between autophagy
and apoptosis. Nat Rev Mol Cell Biol. 8:741–752. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim R, Emi M, Tanabe K, Murakami S, Uchida
Y and Arihiro K: Regulation and interplay of apoptotic and
non-apoptotic cell death. J Pathol. 208:319–326. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thorburn A: Apoptosis and autophagy:
regulatory connections between two supposedly different processes.
Apoptosis. 13:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Boya P, González-Polo RA, Casares N, et
al: Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol.
25:1025–1040. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Amaravadi RK, Yu D, Lum JJ, et al:
Autophagy inhibition enhances therapy-induced apoptosis in a
Myc-induced model of lymphoma. J Clin Invest. 117:326–336. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ravikumar B, Berger Z, Vacher C, O’Kane CJ
and Rubinsztein DC: Rapamycin pre-treatment protects against
apoptosis. Hum Mol Genet. 15:1209–1216. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Longo L, Platini F, Scardino A, Alabiso O,
Vasapollo G and Tessitore L: Autophagy inhibition enhances
anthocyanin-induced apoptosis in hepatocellular carcinoma. Mol
Cancer Ther. 7:2476–2485. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Herman-Antosiewicz A, Johnson DE and Singh
SV: Sulforaphane causes autophagy to inhibit release of cytochrome
c and apoptosis in human prostate cancer cells. Cancer Res.
66:5828–5835. 2006. View Article : Google Scholar
|
|
21
|
Bernstein E, Caudy AA, Hammond SM and
Hannon GJ: Role for a bidentate ribonuclease in the initiation step
of RNA interference. Nature. 409:363–366. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zielske SP and Stevenson M: Importin 7 may
be dispensable for human immunodeficiency virus type 1 and simian
immunodeficiency virus infection of primary macrophages. J Virol.
79:11541–11546. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pullmann R Jr, Juhaszova M, López de
Silanes I, et al: Enhanced proliferation of cultured human vascular
smooth muscle cells linked to increased function of RNA-binding
protein HuR. J Biol Chem. 280:22819–22826. 2005. View Article : Google Scholar
|
|
24
|
Munafo DB and Colombo MI: A novel assay to
study autophagy: regulation of autophagosome vacuole size by amino
acid deprivation. J Cell Sci. 114:3619–3629. 2001.PubMed/NCBI
|
|
25
|
Mizushima M: Methods for monitoring
autophagy. Int J Biochem Cell Biol. 36:2491–2502. 2004. View Article : Google Scholar
|
|
26
|
Klionsky DJ, Abeliovich H, Agostinis P, et
al: Guidelines for the use and interpretation of assays for
monitoring autophagy in higher eukaryotes. Autophagy. 4:151–175.
2008. View Article : Google Scholar
|
|
27
|
Brummelkamp TR, Bernards R and Agami R: A
system for stable expression of short interfering RNAs in mammalian
cells. Science. 296:550–553. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boyd KD, Walker BA, Wardell CP, et al:
High expression levels of the mammalian target of rapamycin
inhibitor DEPTOR are predictive of response to thalidomide in
myeloma. Leuk Lymphoma. 51:2126–2129. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hideshima T, Bradner JE, Wong J, et al:
Small-molecule inhibition of proteasome and aggresome function
induces synergistic antitumor activity in multiple myeloma. Proc
Natl Acad Sci USA. 102:8567–8572. 2005. View Article : Google Scholar
|
|
30
|
Pan Y, Gao Y, Chen L, et al: Targeting
autophagy augments in vitro and in vivo antimyeloma activity of
DNA-damaging chemotherapy. Clin Cancer Res. 17:3248–3258. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kaufman SH: Induction of endonucleolytic
DNA cleavage in human acute myelogenous leukemia cell by etoposide,
camptothecin and other cytotoxic anticancer drugs: a cautionary
note. Cancer Res. 49:5870–5878. 1989.PubMed/NCBI
|
|
32
|
Cheriyath V, Kuhns MA, Kalaycio ME and
Borden EC: Potentiation of apoptosis by histone deacetylase
inhibitors and doxorubicin combination: cytoplasmic cathepsin B as
a mediator of apoptosis in multiple myeloma. Br J Cancer.
104:957–967. 2011. View Article : Google Scholar
|
|
33
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JF: The PTEN/PI3K/Akt signaling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Que W, Chen J, Chuang M and Jiang D:
Knockdown of c-Met enhances sensitivity to bortezomib in human
multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
APMIS. 120:195–203. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
McMillin DW, Ooi M, Delmore J, et al:
Antimyeloma activity of the orally bioavailable dual
phosphatidylinositol 3-kinase/mammalian target of rapamycin
inhibitor NVP-BEZ235. Cancer Res. 69:5835–5842. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
de la Rubia J and Such E: DEPTOR
expression and response to thalidomide: toward a new therapeutic
target in multiple myeloma? Leuk Lymphoma. 51:1960–1961. 2010.
|
|
37
|
Allan LA and Clarke PR: Apoptosis and
autophagy: regulation of caspase-9 by phosphorylation. FEBS J.
276:6063–6073. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Akiyama M, Hideshima T, Hayashi T, et al:
Cytokines modulate telomerase activity in a human multiple myeloma
cell line. Cancer Res. 62:3876–3882. 2002.PubMed/NCBI
|
|
39
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Brunet A, Bonni A, Zigmond MJ, et al: Akt
promotes cell survival by phosphorylating and inhibiting a Forkhead
transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Datta SR, Brunet A and Greenberg ME:
Cellular survival: a play in three Akts. Genes Dev. 13:2905–2927.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kim D and Chung J: Akt: versatile mediator
of cell survival and beyond. J Biochem Mol Biol. 35:106–115. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kang HY, Shim D, Kang SS, Chang SI and Kim
HY: Protein kinase B inhibits endostatin-induced apoptosis in
HUVECs. J Biochem Mol Biol. 39:97–104. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Han B, Wei W, Hua F, et al: Requirement
for ERK activity in sodium selenite-induced apoptosis of acute
promyelocytic leukemia-derived NB4 cells. J Biochem Mol Biol.
40:196–204. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Que WZ and Chen JM: Knockdown of c-Met
inhibits cell proliferation and invasion and increases
chemosensitivity to doxorubicin in human multiple myeloma U266
cells in vitro. Mol Med Rep. 4:343–349. 2011.PubMed/NCBI
|
|
46
|
Knobloch J, Schmitz I, Götz K,
Schulze-Osthoff K and Rüther U: Thalidomide induces limb anomalies
by PTEN stabilization, Akt suppression, and stimulation of
caspase-dependent cell death. Mol Cell Biol. 28:529–538. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Efeyan A and Sabatini DM: mTOR and cancer:
many loops in one pathway. Curr Opin Cell Biol. 22:169–176. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zeng X and Kinsella TJ: Mammalian target
of Rapamycin and S6 Kinase 1 positively regulate
6-thioguanine-induced autophagy. Cancer Res. 68:2384–2390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Guertin DA and Sabatini DM: Defining the
role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar
|
